Macrophage Biomarkers CD68 and CD163 Correlate with CRC Patient Survival (Poster No. 2530 at #AACR2022)

Key Takeaways

CRC patient survival correlates with the presence or absence of macrophage biomarkers CD68, CD163, and a lack of PD-L1.
Lower levels of ‘M1/anti-tumor’ CD68⁺ or CD68⁺CD163^– cells correlate with increased survival. Higher levels of ‘M2/pro-tumor’ CD163⁺ cells showed minimal correlation to survival.
Based on these observations, additional biomarkers are needed to better characterize macrophage phenotypes and understand their role in the tumor microenvironment.

READY TO TAKE THE NEXT STEP?

Our Services

Pharma

Cell-based image analysis, assays, and partnership to advance clinical trials and regulatory acceptance.

Clinical Diagnostics

Dependable clinical diagnostic testing to connect patients to individualized, immuno-oncology therapies.

Flagship carefully tracks our tissue to ensure we can analyze every assay and stay on schedule.

We are trying to bridge from the discovery stage to clinical development. Flagship's pathologists and scientists provide critical input and the company helps us organize and analyze an incredible amount of data. I highly recommend Flagship for its expertise and support for drug development projects.

During clinical trials, I interact with our manufacturing, legal, pre-clinical, and biomarker teams. Our Flagship project manager understands our tight timeline and ensures delivery of the data we need, when we need it.

We are pleased to partner with Flagship Biosciences to integrate their machine learning/AI tools to provide cancer marker detection.

Flagship’s image analysis experts are flexible and willing to work with us to develop projects that meet the changing needs of our clinical trials drug development.

Flagship has a high reputation as a supplier of advanced IHC services and their CAP-CLIA environment is a perfect complement to our own testing facilities.

The ease of leveraging Flagship’s powerful solution is yet another massive differentiator of the company. Clients need not have to change their existing workflows, investments in technology, or even the assays that they use.

POSTERS & PUBLICATIONS